Treatment for relapsed myeloma, fraility, and drugs in development
(click on the image above to view the video)
Recorded at the IMF Satellite Symposium that was held at the May 2018 Oncology Nursing Society’s annual meeting, this video is the third in a three-part series on myeloma nursing. In this segment, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Taussig Cancer Insitute, Cleveland Clinic, Cleveland, OH) and Patricia A. Mangan, RN, MSN, APRN-BC discuss relapsed myeloma, treatment for relapsed myelma, fraility, and drugs in development.
- Multiple Myeloma Background, Shared Decision Making, and Smoldering Update
- Newly Diagnosed and Relapsed Multiple Myeloma
- Treatment for relapsed myeloma, fraility, and drugs in development
This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Oncology, and educational funding donation provided by Amgen Oncology